公开(公告)号：US10947304B2

公开(公告)日：2021-03-16

申请号：US16470996

申请日：2017-12-19

Applicant: UCB BIOPHARMA SRL

Inventor： Neesha Dedi ,  Breda Twomey ,  Michael John Wright ,  Gareth Davies ,  David James McMillan

IPC: C07K16/22 ,  A61P9/12 ,  C07K14/51 ,  G01N33/68 ,  A61K39/00

Abstract: This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

公开(公告)号：US10883996B2

公开(公告)日：2021-01-05

申请号：US15736336

申请日：2015-10-22

Applicant: UCB BIOPHARMA SRL

Inventor： James Philip O'Connell ,  John Robert Porter ,  Alastair Lawson ,  Boris Kroeplien ,  Stephen Edward Rapecki ,  Timothy John Norman ,  David James McMillan ,  Graham John Warrellow ,  Daniel Christopher Brookings ,  Rikki Peter Alexander

IPC: G01N33/68 ,  C07K14/525 ,  C07K14/705 ,  C07K16/24 ,  C07D401/14 ,  C07D471/00 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D471/04 ,  A61K47/64 ,  A61P37/00 ,  A61P35/00

Abstract: The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.

公开(公告)号：US11292831B2

公开(公告)日：2022-04-05

申请号：US16772043

申请日：2018-12-13

Applicant: UCB Biopharma SRL

Inventor： Patrick Downey ,  Kerry Louise Tyson ,  Marco Kriek ,  Lorenzo De Lichtervelde ,  Daniel John Lightwood ,  David James McMillan ,  Peter Charles Elliott ,  Terence Seward Baker

IPC: C07K16/18 ,  A61P25/16 ,  A61K39/00

Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.

公开(公告)号：US11261242B2

公开(公告)日：2022-03-01

申请号：US16771993

申请日：2018-12-13

Applicant: UCB Biopharma SRL

Inventor： Ralph Adams ,  Patrick Downey ,  Terence Seward Baker ,  Kerry Louise Tyson ,  Lorenzo De Lichtervelde ,  Daniel John Lightwood ,  David James McMillan

IPC: C07K16/18 ,  A61K39/00

Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.

公开(公告)号：US11807680B2

公开(公告)日：2023-11-07

申请号：US17172109

申请日：2021-02-10

Applicant: UCB BIOPHARMA SRL

Inventor： Neesha Dedi ,  Breda Twomey ,  Michael John Wright ,  Gareth Charles Glyndwr Davies ,  David James McMillan

IPC: C07K16/22 ,  A61P9/12 ,  C07K14/51 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K16/22 ,  A61P9/12 ,  C07K14/51 ,  G01N33/6854 ,  A61K2039/505 ,  C07B2200/13 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76

Abstract: This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

公开(公告)号：US11732034B2

公开(公告)日：2023-08-22

申请号：US17136189

申请日：2020-12-29

Applicant: UCB BIOPHARMA SRL

Inventor： David Edward Ormonde Knight ,  Terence Seward Baker ,  David James McMillan ,  Robert Anthony Griffin ,  Georges Mairet-Coello ,  Patrick Downey ,  Jean-Philippe Courade

IPC: C07K16/18 ,  C07K14/47 ,  A61P25/28

CPC classification number: C07K16/18 ,  A61P25/28 ,  C07K14/4711 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.